Introduction
Coronary artery disease (CAD), with all of the associated consequences, is a dominant cause of death among adults. Patients presenting with symptoms of that disease can be treated either pharmacologically (PT), with percutaneous coronary intervention (PCI) or with coronary artery bypass graft (CABG). Coronary artery disease in the advanced stages, especially in patients who underwent myocardial infarction, leads to dysfunction of the left ventricle (LV). In patients with coronary artery disease and severe left ventricle dysfunction, who were only treated pharmacologically, the survival rate at two-year follow-up was 31% [1] . In this group of patients, CABG signifi cantly improved systolic function of the left ventricle. On the other hand, patients with severe dysfunction of the LV are not good candidates to perform PCI because of the risk of total coronary artery occlusion during angioplasty, which obviously can be a lethal complication. Two large randomized trials performed before the era of statins and stents, comparing pharmacological management to cardiac surgery [4] and to PCI [5] , reported similar rates of myocardial infarctions and cardiac deaths at one-year follow-up in a MASS II study [6] . However, in these trials, the range of revascularization procedures performed, and the initial clinical characteristics were proved to be different. The majority of randomized trials comparing effect CABG and PCI on survival of patients with CAD excluded patients with severe LV dysfunction. Therefore, there is a lack of data to design an optimal treatment strategy for these patients.
Aim
We performed a retrospective post treatment evaluation of the NYHA Classifi cation and Quality of Life with regard to the chosen method of treatment in patients with documented coronary artery disease.
Materials and methodology
We conducted a single-center observational study of 120 consecutive patients hospitalized in the 2nd Department of Cardiology in Zabrze from [2004] [2005] ; the patients were admitted due to an exacerbation of heart failure to extend the diagnostic process. Among 124 patients hospitalized from 2004-2005 with diagnosed coronary artery disease 4 patients were qualifi ed for orthotopic heart transplantation (OHT) and therefore, were subsequently excluded from further analysis. Approximately one third of patients had symptoms of angina just before admission. The patients underwent routine clinical examination and evaluation for CAD risk factors. Heart failure was evaluated on the basis of the NYHA functional classifi cation. Every patient underwent ECG examination, which was performed using a 6-channel ECG (Mortara Instrument Eli 250); the echocardiography examination was performed using Vivid 4. Subsequently, diagnostics consisted of the invasive examination of coronary arteries (Phillips Allura cardiovascular X-ray system). Patients with LVEF ≤ 30% and atherosclerotic lesions in coronary arteries were qualifi ed for further analysis. Patients were designated for CABG, PCI or pharmacotherapy on the basis of clinical decisions made by cardiologists and surgeons.
Group 1 -Pharmacotherapy Group 2 -CABG Group 3 -PCI Follow-up was conducted by control examination more than 2.5 years after the fi rst hospitalization. The aim of the control examination was to assess the NYHA functional classifi cation and Quality of Life score in comparison to the status before the treatment had been introduced ( Figure 1 ). Five components of the QOL score (energy, pain, dyspnea, mobility, and sleep quality) were analyzed over the follow-up period. Patient responses received from 1 to 5 points on the QOL scale, on which 1 point represents maximal deterioration and 5 points represents maximal amelioration. The sum of all points was used to evaluate the QOL score according to the pattern presented in Table 1 .
Furthermore, the drugs required by patients and the frequency of MACCE (Major Adverse Cardiac and Cerebrovascular Event) occurrences were determined. All patients were on similar pharmacological treatment concordant with guidelines which consisted of beta--blockers (p=0.82), angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (p=0.57), diuretics (p=0.10), anti-platelet drugs (p=0.07), statins (p=0.26), anti-vitamin K (p=0.25) and fi brates (p=0.43). Differences in administration of those drugs are not statistically signifi cant except for nitrates (p=0.01) and calcium blockers (p=0.03). Worth noticing is also the fact that all of these drugs were administered in the maximal tolerated doses. 
Statistical analysis

Results
Finally, 120 patients were enrolled for observation. Among 120 patients, 62 were treated pharmacologically, 25 underwent CABG and 33 were submitted to PCI. The demographic data are presented in Table 2 . The gender distribution varied between the groups; there were no females in group number 2. LVEF measurements performed among the patients did not reveal statistically signifi cant differences between the three groups (p=ns) (Figure 1 ). There were no statistically signifi cant differences in number of vessels with severe atherosclerotic lesions among the three groups of patients (p=ns). However, there was a statistically signifi cant difference in two-vessel CAD: patients with this sort of disease underwent revascularization procedures more often (p=0.0246). NYHA functional classifi cation was comparable in all groups of patients at the beginning of the observation period. The improvement of NYHA functional classifi cation in group of patients submitted to surgical revascularization procedure comparing to those patients who were only pharmacologically treated was statistically signifi cant (p=0.00256) (Figure 2 ). 
AMI -Acute Myocardial Infarction PCI -Percutaneous Coronary Intervention CABG -Coronary Artery Bypass Graft
Improvement of NYHA class was achieved in 20 patients from the pharmacological treatment group comparing to PCI group (p=0.055) and in 19 patients from the CABG comparing to PCI group (p=0.044) although these differences were not statistically significant.
Mean observation time in all three groups was 28,16 months (group 1 -27,48 ± 13,06 months; group 2 -29,9 ± 8,81 months; group 3 -27,12 ± 10,14 months). In total, 26 of MACCE were observed; there were no statistically significant differences among groups (Figure 3) . Quality of Life was assessed after the mean time of 28,16 months in all three groups. Worth noticing that QOL improved in the 58 percent of the patients in the pharmacological treatment group, 40 percent of the patients in the CABG group and 48 percent of the patients in the PCI group. Comparison between the particular groups of patients did not reveal statistically significant differences 1 vs. 2, 2 vs. 3, 1 vs. 3 respectively (p=0.11), (p=0.48), (p=1.0).
Discussion
Despite recent progress in the treatment of patients suffering from coronary artery disease and severe left ventricular dysfunction, the prognosis remains poor [7] . If there are no contraindications (e.g., pulmonary hypertension, malignant tumors or advanced age), these patients are often qualified for orthotopic heart transplantation (OHT). Regrettably, this method is quite limited due to the small number of donors and the necessity for chronic immunosuppression [8] . Revascularization procedures are performed all over the world not only to reduce the mortality rate but also to improve the quality of life. Choosing the method of treatment for the analyzed group of patients was extremely difficult. The patients who were qualified for medical treatment presented complicated clinical problems. In the majority of these cases, neither palliative revascularization nor CABG could be performed due to the presence of multifocal atherosclerotic lesions or to the excessively narrow diameter of the coronary arteries. Evaluations of the range of revascularization were made according to the Heart Team recommendations. The primary criteria were the preserved contractility and viability of the muscle, which were assessed during transthoracic stress echocardiography. After selecting the method to be used for treatment, quality of life (QOL) improved in 50% of patients. This improvement correlates with the results presented by Marwick et al. in which patients, after being asked precisely about quality of life (physical activity, chest pain, general improvement, emotional reactions), also claimed improvement after undergoing surgical revascularization [9] . Dillip et al. also reported improved quality of life in patients with LVEF<30% at the 1-year follow-up after surgical treatment [10] . Previous assessments of quality of life after surgical procedures concentrated on patients with angina. Studies describing revascularization in these patients showed only a moderate correlation of angina with QOL, especially in the analysis of chest pain and physical efficiency. In the BARI trial, QOL improved in a similar way in patients submitted to CABG or PCI [11] . In the RITA study, deterioration of QOL correlated with the presence of angina before and after revascularization, and in patients without chest pain, QOL was not different from the QOL in the control group [12] . Still, there exists a vast population of patients who declare a worsening of QOL despite the treatment. This worsening could be due to emotional stress, which can evolve into a serious adaptive disorder. The crucial fact is that QOL deteriorated in the examined group of patients in 19-40% of cases. In a study by Marwick et al., the presence of neuropsychiatric complications or other difficulties such as unemployment after CABG led nearly 20% of patients to report worsened QOL [9] . Similar to ours results, the amelioration of the NYHA functional classification in one trial was achieved after operational treatment (2.6 ± 0.7 preoperatively and 1.9 ± 0.7 postoperatively) [9] . Notably, in the patients examined here, an improvement in the NYHA functional classification occurred in all three groups, especially in those who underwent revascularization procedures (Figure 2 ). Buszman et al. also reported improvements in the NYHA functional classification in patients with cardiomyopathy submitted to revascularization procedures; this trend was comparable in both groups [13] . A trial that investigated patients included in the Duke Cardiovascular Disease Databank considered 1,400 patient cases similar to those presented in our study. When the results obtained with pharmacological treatment were compared to those achieved with operational treatment, it was apparent that regardless of the level of CAD progression, symptoms of heart failure or LV dysfunction, CABG ensured better results at the 10-year follow-up [14] . Buszman et al. proved that PCI offers better results than CABG as far as 1-year survival is concerned; however, fewer subsequent interventions were needed after CABG was performed [13] . Hueb et al. [15] did not reveal substantial differences with respect to the number of deaths when comparing three strategies for treatment (MT, CABG, PCI). Hueb stated, however, that chest pain recurrence was more common in patients submitted to PCI as compared to those who underwent CABG but was similar to those patients treated only with MT. In our study, we observed fewer deaths in patients submitted to the revascularization procedure, although this trend was not statistically significant; MACCE occurred in a similar percentage of cases. Analysis of the number of significantly stenosed coronary arteries revealed that there were important differences between presented groups only among those treated with two--vessel CAD. Revascularization procedures (CABG or PCI) were performed more frequently among these patients. Malenka et al. indicated that patients with three-vessel CAD more frequently underwent CABG than those who had undergone two-vessel CAD -PCI [16] . We believe patients with LV dysfunction and CAD should be considered as a special priority. Choosing the proper method of treatment is extremely difficult. It is advisable to pay more attention to the self-evaluation of each patient's health condition, which often differs from the strictly medical objectives of treatment.
Conclusions
In conclusion, the improvement of NYHA functional class in patients with severe left ventricular dysfunction is statistically significant in patients submitted to surgical revascularization comparing to pharmacological treatment (p=0,00256). Differences in Quality of Life among groups of patients regarding to method of treatment are not statistically significant.
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